AEON Biopharma Provides Update on Development Pipeline
09 mai 2024 08h00 HE
|
AEON Biopharma
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum...
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
03 mai 2024 07h00 HE
|
AEON Biopharma
IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum...
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
30 mars 2024 22h53 HE
|
AEON Biopharma
IRVINE, Calif., March 30, 2024 (GLOBE NEWSWIRE) -- Regarding a release issued under the same headline on March 29, 2024 by AEON Biopharma, Inc. (NYSE: AEON; AEON.WS), please note that in the first...
AEON Biopharma Announces Redemption of Public Warrants
29 mars 2024 16h15 HE
|
AEON Biopharma
IRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON; AEON.WS) (“AEON” or “the Company”), a clinical-stage biopharmaceutical company focused on developing a...
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
29 mars 2024 15h45 HE
|
AEON Biopharma
– Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine – ...
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
19 mars 2024 16h30 HE
|
AEON Biopharma
– FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine – – An interim analysis from the ongoing...
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements
19 mars 2024 16h29 HE
|
AEON Biopharma
-- Termination of the Forward Purchase Agreements simplifies AEON’s capitalization structure -- -- AEON to expand its Board of Directors with appointment of candidate selected by its strategic...
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference
18 janv. 2024 16h05 HE
|
AEON Biopharma
– Open label extension (OLE) Phase 2 data show peak efficacy for all ABP-450 doses and cycles in treating cervical dystonia (CD) occurred early, within 4 weeks; durability of effect was demonstrated...
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine
12 déc. 2023 08h00 HE
|
AEON Biopharma
– Expect to announce topline data in Q3 2024 – – Company plans in Q1 2024 an end-of-phase 2 meeting with the FDA to discuss the Phase 3 program in episodic migraine – – Anticipate shortening the...
AEON Biopharma Reports Third Quarter 2023 Financial Results
13 nov. 2023 08h15 HE
|
AEON Biopharma
– Announced topline results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the preventive treatment of episodic migraine that support advancing the program into a pivotal Phase 3 study – –...